Bioclinica Launches Post-Approval Research Division
Bioclinica has built a post-approval study-specific technology platform along with a Program Coordinating Center (PCC) with dedicated and experienced post-approval research staff.
Bioclinica®, a specialty clinical trials services and technology provider, has created a Post-Approval Research division of its Global Clinical Research business segment to meet the growing and ever-evolving needs of the post-approval research industry. Leveraging its technology expertise, Bioclinica has built a post-approval study-specific technology platform along with a Program Coordinating Center (PCC) with dedicated and experienced post-approval research staff. The PCC provides global operational infrastructure from centralized locations to support local languages and time differences. In addition, a unique service offering of the Post-Approval Research division is the development of the Patient Outreach Center (POC).
Read the full release.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
